Navigation Links
Usage Of Oral Contraceptives Need Not Be Feared By SLE Patients

In a research co headed by Jill Buyon, M.D., of New York’s Hospital for Joint Diseases said that oral contraceptives can be given to women with inactive or stable Systemic// Lupus Erythematosus (SLE) and they would not show symptoms of increased risk of flares of the disease.

This research was funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), a part of the National Institutes of Health (NIH). In this disease the body fails to recognize as self and starts to attack its own tissues of the skin, joints and other internal organs.

Initially clinicians are very hesitant to give contraceptive pills (orally) to the patients with SLE because of the fear that they might show increased and unwanted disease activity.

This study which included 183 women with inactive or stable SLE were given oral contraceptives (triphasic 35 μg.ethinylestradiol/0.5-1 mg norethindrone for twelve 28-day cycles).they did not show any difference in reaction when compared to the controls who were given placebo.

Seven percent of the women showed severe reaction in both the test as well as in control categories. They suffered from various symptoms like new or worsening central nervous system involvement; inflammation of the blood vessels (vasculitis), kidneys (nephritis) and/or muscles (myositis); and/or blood problems, low platelet count (thrombocytopenia) and complete destruction of the red blood cells (hemolytic anemia).

Moderate reactions were seen in both the categories over the one year follow up session which includes fevers, inflammation of the skin, joints, pericarditis, and mucous membranes lining the nose and mouth.

This disease is very common among women. The ratio of women to men suffering from this disease is 10:1. Women usually suffer during the child bearing age when the female hormones are at its peak.

When experiments were conducted with mouse with SLE they showed increased reaction when administered with estrogen. They also affected the B cells which plays a vital role in the disease process.

According to this study it is clearly seen that women suffering with inactive or stable SLE can take estrogen without any fear of increased reaction due to the disease. But on the other hand women suffering from a risk of blood clots are not supposed to take oral contraceptives as estrogen increases blood clot formation.

Hence in conclusion this study has improved the quality of the life of people with rheumatic disease
'"/>




Related medicine news :

1. Usage of coil better in brain haemorrhage
2. Oxygen Usage During Exercise Could Indicate Heart Problems
3. The Usage Of Anti-Inflammatory Drugs Questioned
4. Drug Pramipexole Usage Linked To Gambling Addiction In Parkinsons Patients
5. Generic Drugs Usage In US Can Save $20 Billion – Express Script Surve
6. Safety Of Indian Sex Workers At Risk Due To Poor Condom Usage
7. Dummy Usage Raises Doubts.
8. More The Usage More The Growth In The Adult Brain.
9. Ignorance in the Usage of Pill Persists Among Many Women
10. Vaticans Council Reviews Condom Usage
11. Large Scale Free Access On Usage Of HIV Drugs Could Help In Fighting Its Spread
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/9/2016)... ... December 09, 2016 , ... MEDI+SIGN®, a provider ... that a new solution for Emergency Departments (ED) has been added to their ... Emergency Department examination rooms, and with a simplified pallet of information available to ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... with distinction by the Undersea and Hyperbaric Medical Society (UHMS), the leading authority ... care and patient safety. Only a few hospitals and facilities have earned this ...
(Date:12/8/2016)... ... December 08, 2016 , ... Seavest ... Property owned by an affiliate of Seavest, has won a prestigious national healthcare ... Chester County ambulatory care center (ACC) was named “Best New Development, MOBs and ...
(Date:12/8/2016)... ... December 08, 2016 , ... David J. Dykeman , ... Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, 2016, at the Fairmont ... and attorneys from the firm’s global Life Sciences & Medical Technology Group have been ...
(Date:12/8/2016)... ... 2016 , ... Catalent Pharma Solutions, the leading global provider ... products, today announced that it had joined the Pharmaceutical Supply Chain Initiative (PSCI). ... unite pharmaceutical and healthcare companies that share a vision of better, social, environmental ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016 KEY FINDINGS ... the largest share of the market in 2016 and ... dominance can be attributed to a large number of ... (US hold the largest share in the patient temperature ... benefits such as reducing loss of blood during surgeries, ...
(Date:12/8/2016)... 8, 2016 Research and Markets has announced ... Trends - Adhesion Type, Application, Usability - Forecast to 2025" ... , ... Market is poised to grow at a CAGR of around 3.2% ... market is witnessing include advancements in extracellular microelectrode arrays and intracellular ...
(Date:12/8/2016)... Quebec , Dec. 8, 2016  Valeant ... and TSX: VRX) ("Valeant") today announced positive results ... clinical study to assess the safety and efficacy ... the treatment of plaque psoriasis. ... subjects with moderate to severe psoriasis, IDP-118 showed ...
Breaking Medicine Technology: